{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+CLL&page=11",
    "query": {
      "condition": "Relapsed CLL",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 674,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+CLL&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+CLL&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T03:57:46.986Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03277729",
      "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Transformed Non-Hodgkin Lymphoma",
        "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Transformed Chronic Lymphocytic Leukemia",
        "Refractory Marginal Zone Lymphoma",
        "Refractory Transformed B-Cell Non-Hodgkin Lymphoma",
        "Refractory Transformed Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma",
        "Recurrent Central Nervous System Lymphoma",
        "Refractory Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2017-12-05",
      "completion_date": "2039-03",
      "has_results": true,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03277729"
    },
    {
      "nct_id": "NCT04732845",
      "title": "Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Acute Lymphoblastic Leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Fully human anti CD19 CAR-T Cell Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Benjamin Tomlinson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-04-26",
      "completion_date": "2040-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04732845"
    },
    {
      "nct_id": "NCT00060372",
      "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Childhood Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Disseminated Neuroblastoma",
        "Malignant Neoplasm",
        "Ovarian Choriocarcinoma",
        "Ovarian Embryonal Carcinoma",
        "Ovarian Immature Teratoma",
        "Ovarian Mature Teratoma",
        "Ovarian Mixed Germ Cell Tumor",
        "Ovarian Monodermal and Highly Specialized Teratoma",
        "Ovarian Polyembryoma",
        "Ovarian Yolk Sac Tumor",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Neuroblastoma",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage II Ovarian Epithelial Cancer",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Multiple Myeloma",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Testicular Choriocarcinoma",
        "Testicular Choriocarcinoma and Embryonal Carcinoma",
        "Testicular Choriocarcinoma and Seminoma",
        "Testicular Choriocarcinoma and Teratoma",
        "Testicular Choriocarcinoma and Yolk Sac Tumor",
        "Testicular Embryonal Carcinoma",
        "Testicular Embryonal Carcinoma and Seminoma",
        "Testicular Embryonal Carcinoma and Teratoma",
        "Testicular Embryonal Carcinoma and Teratoma With Seminoma",
        "Testicular Embryonal Carcinoma and Yolk Sac Tumor",
        "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma",
        "Testicular Teratoma",
        "Testicular Yolk Sac Tumor",
        "Testicular Yolk Sac Tumor and Teratoma",
        "Testicular Yolk Sac Tumor and Teratoma With Seminoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-27",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060372"
    },
    {
      "nct_id": "NCT01241786",
      "title": "Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia(CLL)",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Revlimid",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2010-07",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01241786"
    },
    {
      "nct_id": "NCT02227108",
      "title": "Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Pediatric ALL"
      ],
      "interventions": [
        {
          "name": "Moxetumomab Pasudotox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 37,
      "start_date": "2014-08",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227108"
    },
    {
      "nct_id": "NCT03601819",
      "title": "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, T-Cell, Cutaneous",
        "Lymphoma, T-Cell, Peripheral",
        "Chronic Lymphocytic Leukemia",
        "Lymphoproliferative Disorders",
        "Waldenstrom Macroglobulinemia",
        "Lymphoplasmacytic Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-05-15",
      "completion_date": "2020-07-17",
      "has_results": false,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601819"
    },
    {
      "nct_id": "NCT06839053",
      "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Small Lymphocytic Lymphoma",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gastrointestinal Endoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sonrotoclax",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-02",
      "completion_date": "2032-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06839053"
    },
    {
      "nct_id": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)",
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
        "Mantle Cell Lymphoma (MCL)",
        "Richter's Syndrome",
        "T-cell Lymphoma",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Marginal Zone Lymphoma",
        "Myeloid Malignancies",
        "Acute Myeloid Leukemia (AML)",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "Myelodysplastic Syndrome (MDS)",
        "MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome"
      ],
      "interventions": [
        {
          "name": "PRT2527",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2023-09-12",
      "completion_date": "2026-01-21",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05665530"
    },
    {
      "nct_id": "NCT03997968",
      "title": "A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignancy",
        "Non-hodgkin Lymphoma",
        "Multiple Myeloma",
        "Breast Cancer",
        "Ovarian Cancer",
        "Soft Tissue Sarcoma",
        "Head and Neck Cancer",
        "DLBCL",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Pancreatic Cancer",
        "CLL",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "CYT-0851",
          "type": "DRUG"
        },
        {
          "name": "CYT-0851 in combination with gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "CYT-0851 in combination with capecitabine",
          "type": "DRUG"
        },
        {
          "name": "CYT-0851 in combination with rituximab and bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cyteir Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2019-10-09",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997968"
    },
    {
      "nct_id": "NCT00935090",
      "title": "3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "3'-deoxy-3'-[18F]fluorothymidine",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2009-09",
      "completion_date": "2027-04-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-31T03:57:46.986Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00935090"
    }
  ]
}